IL314136A - אימידאזול מקרוציקלים לטיפול במחלות אוטואימוניות - Google Patents
אימידאזול מקרוציקלים לטיפול במחלות אוטואימוניותInfo
- Publication number
- IL314136A IL314136A IL314136A IL31413624A IL314136A IL 314136 A IL314136 A IL 314136A IL 314136 A IL314136 A IL 314136A IL 31413624 A IL31413624 A IL 31413624A IL 314136 A IL314136 A IL 314136A
- Authority
- IL
- Israel
- Prior art keywords
- macrocycles
- imidazole
- treatment
- autoimmune diseases
- autoimmune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022075304 | 2022-02-02 | ||
| CN2022137604 | 2022-12-08 | ||
| PCT/EP2023/052218 WO2023148129A1 (en) | 2022-02-02 | 2023-01-31 | Imidazole macrocycles for the treatment of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314136A true IL314136A (he) | 2024-09-01 |
Family
ID=85175764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314136A IL314136A (he) | 2022-02-02 | 2023-01-31 | אימידאזול מקרוציקלים לטיפול במחלות אוטואימוניות |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4472739A1 (he) |
| JP (1) | JP2025506393A (he) |
| KR (1) | KR20240145483A (he) |
| CN (1) | CN120641428A (he) |
| AR (1) | AR128413A1 (he) |
| AU (1) | AU2023215702A1 (he) |
| CA (1) | CA3250448A1 (he) |
| CL (1) | CL2024002334A1 (he) |
| CO (1) | CO2024011088A2 (he) |
| CR (1) | CR20240312A (he) |
| IL (1) | IL314136A (he) |
| MX (1) | MX2024009404A (he) |
| PE (1) | PE20241762A1 (he) |
| TW (1) | TW202342483A (he) |
| WO (1) | WO2023148129A1 (he) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026523856A (ja) * | 2023-07-10 | 2026-07-15 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための二環式大環状化合物 |
| AR133266A1 (es) * | 2023-07-19 | 2025-09-10 | Hoffmann La Roche | Macrociclos para el tratamiento de enfermedades autoinmunitarias |
| WO2025021666A1 (en) * | 2023-07-21 | 2025-01-30 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
| WO2025068132A1 (en) | 2023-09-26 | 2025-04-03 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
| US20250333398A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228895A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201900628RA (en) * | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2019053617A1 (en) * | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
-
2023
- 2023-01-31 IL IL314136A patent/IL314136A/he unknown
- 2023-01-31 CR CR20240312A patent/CR20240312A/es unknown
- 2023-01-31 PE PE2024001698A patent/PE20241762A1/es unknown
- 2023-01-31 KR KR1020247028861A patent/KR20240145483A/ko active Pending
- 2023-01-31 JP JP2024545970A patent/JP2025506393A/ja active Pending
- 2023-01-31 CN CN202380019951.0A patent/CN120641428A/zh active Pending
- 2023-01-31 CA CA3250448A patent/CA3250448A1/en active Pending
- 2023-01-31 EP EP23703543.1A patent/EP4472739A1/en active Pending
- 2023-01-31 WO PCT/EP2023/052218 patent/WO2023148129A1/en not_active Ceased
- 2023-01-31 MX MX2024009404A patent/MX2024009404A/es unknown
- 2023-01-31 AU AU2023215702A patent/AU2023215702A1/en active Pending
- 2023-02-01 AR ARP230100230A patent/AR128413A1/es unknown
- 2023-02-01 TW TW112103466A patent/TW202342483A/zh unknown
-
2024
- 2024-08-02 CL CL2024002334A patent/CL2024002334A1/es unknown
- 2024-08-15 CO CONC2024/0011088A patent/CO2024011088A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240145483A (ko) | 2024-10-07 |
| AU2023215702A1 (en) | 2024-07-25 |
| TW202342483A (zh) | 2023-11-01 |
| AR128413A1 (es) | 2024-05-08 |
| JP2025506393A (ja) | 2025-03-11 |
| WO2023148129A1 (en) | 2023-08-10 |
| CR20240312A (es) | 2024-09-04 |
| CA3250448A1 (en) | 2023-08-10 |
| EP4472739A1 (en) | 2024-12-11 |
| MX2024009404A (es) | 2024-08-14 |
| CO2024011088A2 (es) | 2024-08-30 |
| CN120641428A (zh) | 2025-09-12 |
| PE20241762A1 (es) | 2024-08-28 |
| CL2024002334A1 (es) | 2025-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024296084A1 (en) | Macrocycles for the treatment of autoimmune disease | |
| IL286340A (he) | פורמולציות מקומיות לטיפול במחלות מערכת העצבים ההיקפית | |
| HUE059638T2 (hu) | Ízületi gyulladásos betegségek kombinált kezelése | |
| EP4230406C0 (en) | MULTI-LAYER SILICONE BODY | |
| EP3843737A4 (en) | PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE | |
| EP4493175A4 (en) | MIRDAMETINIB TREATMENT | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| EP3735209A4 (en) | TREATMENT OF THE PROGRESSION OF MYOPOIA | |
| IL310870A (he) | תרכובות קווינאזולין לטיפול במחלות | |
| EP4021858A4 (en) | TREATMENT OF AZOLES | |
| EP4061821C0 (en) | SPIRO(ISOBENZOFURAN AZETIDINE) COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | |
| EP4225129A4 (en) | OCT GUIDED THERAPY | |
| IL321560A (he) | טיפול במחלות אוטואימוניות | |
| IL325421A (he) | טיפול משולב | |
| EP4404931C0 (en) | AZOLO COMPOUNDS FOR THE TREATMENT OF FIBROTIC DISEASES | |
| EP4051387C0 (en) | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | |
| AU2022296903A1 (en) | Treatment for autoimmune diseases | |
| IL307750A (he) | טיפול בזאבת עורית erythematous | |
| EP4236951A4 (en) | PDE9 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | |
| IL299632A (he) | טיפול במחלות דלקתיות באמצעות נוגדנים נגד גורמים רקמתיים | |
| EP4135553C0 (en) | SKIN TREATMENT SYSTEM | |
| MA56179A (fr) | Traitement de synucléinopathies | |
| IL308571A (he) | שיטות לטיפול או מניעה של מחלות אוטואימוניות | |
| EP4448100A4 (en) | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | |
| JP1756222S (ja) | スキントリートメント器具用クレードル |